How many drugs are losing patent protection in 2029?

Drug Landscape tracks 62 marketed drugs with at least one patent expiring in 2029, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-14 · How we verify

2029 Pharmaceutical Patent Cliff

62 marketed drugs with patents expiring in 2029, joined to sponsor + therapeutic area + drug class. Forward-looking forecast. Sourced from FDA Orange Book + USPTO Patent Public Search.

62 drugs 167 patents 15 therapeutic areas Forward-looking

By therapeutic area

Metabolic (16)

2029-02-01 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
2029-02-04 — Byetta · AstraZeneca · GLP-1 Receptor Agonist [EPC]
2029-02-05 — Tygacil · Pfizer · Tetracycline
2029-02-26 — Cuvposa · Shionogi · Anticholinergic
2029-02-26 — Glycopyrrolate · Yonsei University · Formulation
2029-03-12 — NITROGLYCERIN · Nitrate Vasodilator [EPC] · Formulation
2029-03-12 — Nitroglycerin · Fougera · Nitrate Vasodilator [EPC]
2029-03-27 — Valium · Generic (originally Roche) · Benzodiazepine [EPC] · Formulation
2029-03-29 — Amphetamine Sulfate · UCB · Central Nervous System Stimulant
2029-04-02 — Ongentys · Neurocrine Biosciences · Catechol-O-Methyltransferase Inhibitor [EPC]
2029-08-09 — Zuragard · isopropanol
2029-10-05 — Aceon · Symplmed Pharms Llc · Angiotensin Converting Enzyme Inhibitor
2029-11-19 — Primaxin · Merck & Co. · Renal Dehydropeptidase Inhibitor
2029-11-19 — Primaxin · Merck Sharp & Dohme B.V. · imipenem
2029-12-22 — Reglan · Hikma · Prokinetic agent · Formulation
2029-12-30 — Ibsrela · Ardelyx Inc

Oncology (14)

2029-01-30 — Lymphoseek Kit · Navidea Biopharms · Radioactive Diagnostic Agent
2029-02-01 — Mitozytrex · Kyowa Kirin Co., Ltd. · Alkylating Drug [EPC] · Formulation
2029-02-11 — Spy Agent Green Kit · Renew Pharms · Diagnostic Dye · Method of Use
2029-02-14 — Rapamune · Pfizer · mTOR Inhibitor Immunosuppressant [EPC] · Formulation
2029-02-24 — Arthrotec · Pfizer · diclofenac
2029-03-10 — Trexall · Generic (originally Lederle Laboratories) · Antifolate, DMARD · Formulation
2029-05-14 — Vidaza · Bristol-Myers Squibb · Nucleoside Metabolic Inhibitor [EPC] · Formulation
2029-05-17 — Viekira Pak (Copackaged) · AbbVie · Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor
2029-06-02 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
2029-07-24 — Zepatier · Merck & Co. · Hepatitis C Virus NS5A Inhibitor [EPC]
2029-07-27 — Talzenna · Pfizer · Poly(ADP-Ribose) Polymerase Inhibitor
2029-08-18 — Aldara · Bausch Health · imiquimod · Method of Use
2029-08-20 — Kisqali · Novartis · Kinase Inhibitor
2029-09-22 — Lonsurf · Taiho Oncology Inc · Nucleoside Analog Antiviral [EPC]

Neuroscience (10)

2029-01-07 — Lamictal · GSK · Anti-epileptic Agent [EPC] · Formulation
2029-02-03 — Inbrija · Merz · Aromatic Amino Acid [EPC] · Method of Use
2029-03-05 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Formulation
2029-03-12 — Rilutek · Covis · Benzothiazole [EPC] · Formulation
2029-03-13 — Tegretol · Novartis AG (originally Geigy) · Mood Stabilizer [EPC] · Formulation
2029-03-18 — Neuraceq · Piramal Imaging · Radioactive Diagnostic Agent [EPC]
2029-04-10 — Bupivacaine Hydrochloride And Epinephrine · Pfizer Inc. · alpha-Adrenergic Agonist [EPC] · Formulation
2029-04-21 — Cipro · Bayer AG · Fluoroquinolone antibiotic · Formulation
2029-05-19 — Tauvid · Avid Radiopharms Inc
2029-10-22 — Lignospan Forte · Fresenius Kabi · local anesthetic, amide type · Method of Use

Immunology (6)

2029-03-11 — Acetaminophen · Polymedica · acetaminophen
2029-03-12 — Viramune · Boehringer Ingelheim · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] · Method of Use
2029-03-29 — Tussionex Pennkinetic · Bayer · Histamine-1 Receptor Antagonist
2029-05-07 — Pulmicort Respules · AstraZeneca K.K. · Corticosteroid [EPC] · Formulation
2029-06-02 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation
2029-09-30 — Advil · Generic (originally Boots Group) · Nonsteroidal Anti-inflammatory Drug [EPC] · Method of Use

Respiratory (3)

2029-02-26 — Breo Ellipta · Glaxo Grp Ltd · beta2-Adrenergic Agonist
2029-08-13 — Symdeko (Copackaged) · Vertex Pharms
2029-08-13 — Trikafta (Copackaged) · Vertex Pharms Inc

Bone (2)

2029-02-02 — Ortho-Novum 10/11-21 · Merck & Co. · Estrogen
2029-09-14 — Jadelle · Fdn Consumer · Progestin · Formulation

Infectious Disease (2)

2029-02-05 — Tygacil · Fresenius Kabi · Tetracycline-class Antibacterial [EPC]
2029-11-19 — Recarbrio · Merck & Co. · Renal Dehydropeptidase Inhibitor [EPC]

Gastroenterology (2)

2029-02-26 — Xifaxan · Bausch Health · Rifamycin Antibacterial [EPC] · Method of Use
2029-11-23 — Zofran · GSK (originally Glaxo) · 5-HT3 receptor antagonist (antiemetic) · Formulation

Women's Health (1)

2029-02-03 — Endometrin · Ferring · Progesterone [EPC] · Method of Use

Dermatology (1)

2029-02-28 — Azelex · Leo Pharma As · azelaic acid · Method of Use

Cardiovascular (1)

2029-04-10 — Epipen · Pfizer Inc. · alpha-Adrenergic Agonist [EPC] · Formulation

Pain (1)

2029-04-10 — Naloxone Hydrochloride · Pfizer Inc. · Mixed opioid agonist-antagonist with opioid antagonist · Formulation

Hematology (1)

2029-05-13 — Ferrlecit · Vifor Fresenius · Phosphate Binder [EPC]

Ophthalmology (1)

2029-05-20 — Bupivacaine Hydrochloride · Pfizer · Amide-type local anesthetic